Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Grimwade

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade, Jelena V Jovanovic, Robert K Hills, et al.
Blood|November 4, 2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays, Neil Osheroff, Yuanyuan Xiao, et al.
British Journal of Haematology|November 28, 2008
Elevated FOSB-expression; a potential marker of valproate sensitivity in AMLFarhat L Khanim, Charlotte A Bradbury, Julie Arrazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 MutationsSylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Genes, Chromosomes & Cancer|June 15, 2010
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA lociSyed Khizer Hasan, Tiziana Ottone, Richard F Schlenk, et al.
British Journal of Haematology|December 28, 2016
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemiaAna P Lange, Ana S Lima, Antonio R Lucena-Araujo, et al.
Nature Genetics|April 20, 2010
Mutation of the RAD51C gene in a Fanconi anemia-like disorderFiona Vaz, Helmut Hanenberg, Beatrice Schuster, et al.
Blood|May 24, 2018
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APLAnna Maria Testi, Andrea Pession, Daniela Diverio, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade, Jelena V Jovanovic, Robert K Hills, et al.
Blood|November 4, 2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays, Neil Osheroff, Yuanyuan Xiao, et al.
British Journal of Haematology|November 28, 2008
Elevated FOSB-expression; a potential marker of valproate sensitivity in AMLFarhat L Khanim, Charlotte A Bradbury, Julie Arrazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 MutationsSylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Genes, Chromosomes & Cancer|June 15, 2010
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA lociSyed Khizer Hasan, Tiziana Ottone, Richard F Schlenk, et al.
British Journal of Haematology|December 28, 2016
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemiaAna P Lange, Ana S Lima, Antonio R Lucena-Araujo, et al.
Nature Genetics|April 20, 2010
Mutation of the RAD51C gene in a Fanconi anemia-like disorderFiona Vaz, Helmut Hanenberg, Beatrice Schuster, et al.
Blood|May 24, 2018
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APLAnna Maria Testi, Andrea Pession, Daniela Diverio, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Blood|March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsTimothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Pageof 11